The 81st Annual Meeting of the Japanese Society of Hematology

Presentation information

Print

Luncheon Seminar

LS3-1 New Treatment Option for refractory/relapse DLBCL ―CAR-T cell therapy―

Sun. Oct 13, 2019 12:25 PM - 1:10 PM No.1 (Tokyo International Forum, 4F Hall C)

Chair: Keiya Ozawa（Division of Immuno-Gene & Cell therapy (Takara Bio), Jichi Medical University）

Sponsor: Novartis Pharma K.K.

[LS3-1] New Treatment Option for refractory/relapse DLBCL ―CAR-T cell therapy―

Takanori Teshima (Hokkaido University Hospital Department of Hematology)

Abstract password authentication.
Password is required to view the abstract. Please enter a password to authenticate.Password is written on a program book.

Password